Literature DB >> 26776848

Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS database.

Valery Vilchez1, Malay B Shah1, Michael F Daily1, Luis Pena2, Ching-Wei D Tzeng1, Daniel Davenport1, Peter J Hosein3, Roberto Gedaly1, Erin Maynard4.   

Abstract

BACKGROUND: Mixed hepatocellular and cholangiocarcinoma (HCC-CC) have been associated with a poor prognosis after liver transplantation (LT). We aimed to evaluate long-term outcomes in patients undergoing LT for HCC-CC versus patients with hepatocellular carcinoma (HCC) or cholangiocarcinoma (CC).
METHODS: Retrospective analysis of the United Network for Organ Sharing (UNOS) database from 1994-2013. Overall survival (OS) in patients with HCC-CC, HCC, and CC, were compared.
RESULTS: We identified 4049 patients transplanted for primary malignancy (94 HCC-CC; 3515 HCC; 440 CC). Mean age of patients with HCC-CC was 57 ± 10 years, and 77% were male. MELD score did not differ among the groups (p = 0.637). Hepatitis C virus was the most common secondary diagnosis within the HCC-CC (44%) and HCC (36%) cohorts, with primary sclerosing cholangitis in the CC (16%) cohort. OS rates at 1, 3 and 5 years for HCC-CC (82%, 47%, 40%) were similar to CC (79%, 58%, 47%), but significantly worse than HCC (86%, 72%, and 62% p = 0.002). DISCUSSION: Patients undergoing LT for HCC had significantly better survival compared to those transplanted for HCC-CC and CC. LT for mixed HCC-CC confers a survival rate similar to selected patients with CC. Efforts should be made to identify HCC-CC patients preoperatively.
Copyright © 2015. Published by Elsevier Ltd.

Entities:  

Mesh:

Year:  2016        PMID: 26776848      PMCID: PMC4750226          DOI: 10.1016/j.hpb.2015.10.001

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  26 in total

Review 1.  Liver transplantation for cholangiocarcinoma.

Authors:  Charles B Rosen; Julie K Heimbach; Gregory J Gores
Journal:  Transpl Int       Date:  2010-05-20       Impact factor: 3.782

Review 2.  Liver transplantation for non-hepatocellular carcinoma malignancy: Indications, limitations, and analysis of the current literature.

Authors:  Eric J Grossman; J Michael Millis
Journal:  Liver Transpl       Date:  2010-08       Impact factor: 5.799

3.  A clinicopathological study on combined hepatocellular and cholangiocarcinoma.

Authors:  J Taguchi; O Nakashima; M Tanaka; T Hisaka; T Takazawa; M Kojiro
Journal:  J Gastroenterol Hepatol       Date:  1996-08       Impact factor: 4.029

4.  Clinical and pathological analysis of 27 patients with combined hepatocellular-cholangiocarcinoma in an Asian center.

Authors:  Qian Zhan; Bai-Yong Shen; Xia-Xing Deng; Zhe-Cheng Zhu; Hao Chen; Chen-Hong Peng; Hong-Wei Li
Journal:  J Hepatobiliary Pancreat Sci       Date:  2012-07       Impact factor: 7.027

5.  The diagnostic conundrum and liver transplantation outcome for combined hepatocellular-cholangiocarcinoma.

Authors:  C Panjala; D L Senecal; M D Bridges; G P Kim; R E Nakhleh; J H H Nguyen; D M Harnois
Journal:  Am J Transplant       Date:  2010-05       Impact factor: 8.086

Review 6.  Clinical diagnosis and staging of cholangiocarcinoma.

Authors:  Boris Blechacz; Mina Komuta; Tania Roskams; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-08-02       Impact factor: 46.802

7.  Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma.

Authors:  Gonzalo Sapisochin; Nicholas Fidelman; John P Roberts; Francis Y Yao
Journal:  Liver Transpl       Date:  2011-08       Impact factor: 5.799

8.  Transplantation versus resection for patients with combined hepatocellular carcinoma-cholangiocarcinoma.

Authors:  Ryan T Groeschl; Kiran K Turaga; T Clark Gamblin
Journal:  J Surg Oncol       Date:  2013-02-05       Impact factor: 3.454

9.  Liver transplantation for combined hepatocellular cholangiocarcinoma.

Authors:  Albert Chi-Yan Chan; Chung Mau Lo; Irene Oi-Lin Ng; Sheung Tat Fan
Journal:  Asian J Surg       Date:  2007-04       Impact factor: 2.767

10.  Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma.

Authors:  Ki Hun Kim; Sung Gyu Lee; Eun Hwa Park; Shin Hwang; Chul Soo Ahn; Deok Bog Moon; Tae Yong Ha; Gi Won Song; Dong Hwan Jung; Kang Mo Kim; Young Suk Lim; Han Chu Lee; Young Hwa Chung; Yung Sang Lee; Dong Jin Suh
Journal:  Ann Surg Oncol       Date:  2009-01-06       Impact factor: 5.344

View more
  23 in total

1.  Systemic therapy for unresectable, mixed hepatocellular-cholangiocarcinoma: treatment of a rare malignancy.

Authors:  Jane E Rogers; Ryan M Bolonesi; Asif Rashid; Khaled M Elsayes; Mohamed G Elbanan; Lindsey Law; Ahmed Kaseb; Rachna T Shroff
Journal:  J Gastrointest Oncol       Date:  2017-04

2.  How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI?

Authors:  Hong Seon Lee; Myeong-Jin Kim; Chansik An
Journal:  Eur Radiol       Date:  2018-12-14       Impact factor: 5.315

3.  Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018.

Authors:  Daniel R Ludwig; Tyler J Fraum; Roberto Cannella; David H Ballard; Richard Tsai; Muhammad Naeem; Maverick LeBlanc; Amber Salter; Allan Tsung; Anup S Shetty; Amir A Borhani; Alessandro Furlan; Kathryn J Fowler
Journal:  Abdom Radiol (NY)       Date:  2019-06

4.  Management of combined hepatocellular carcinoma-cholangiocarcinoma.

Authors:  Ju Dong Yang; Lewis R Roberts
Journal:  Curr Hepatol Rep       Date:  2018-10-17

Review 5.  Liver Transplantation for Cholangiocarcinoma: Insights into the Prognosis and the Evolving Indications.

Authors:  Guergana G Panayotova; Flavio Paterno; James V Guarrera; Keri E Lunsford
Journal:  Curr Oncol Rep       Date:  2020-04-16       Impact factor: 5.075

Review 6.  Combined hepatocellular cholangiocarcinoma: Controversies to be addressed.

Authors:  An-Qiang Wang; Yong-Chang Zheng; Juan Du; Cheng-Pei Zhu; Han-Chun Huang; Shan-Shan Wang; Liang-Cai Wu; Xue-Shuai Wan; Hao-Hai Zhang; Ruo-Yu Miao; Xin-Ting Sang; Hai-Tao Zhao
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

7.  Mixed hepatocellular and cholangiocarcinoma: a rare tumor with a mix of parent phenotypic characteristics.

Authors:  John R Bergquist; Ryan T Groeschl; Tommy Ivanics; Christopher R Shubert; Elizabeth B Habermann; Michael L Kendrick; Michael B Farnell; David M Nagorney; Mark J Truty; Rory L Smoot
Journal:  HPB (Oxford)       Date:  2016-08-18       Impact factor: 3.647

Review 8.  Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma.

Authors:  Shweta Gera; Mark Ettel; Gabriel Acosta-Gonzalez; Ruliang Xu
Journal:  World J Hepatol       Date:  2017-02-28

9.  Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience.

Authors:  Thomas T DeLeon; Marcela A Salomao; Bashar A Aqel; Mohamad B Sonbol; Raquel T Yokoda; Ahmad H Ali; Adyr A Moss; Amit K Mathur; David M Chascsa; Jorge Rakela; Alan H Bryce; Mitesh J Borad
Journal:  J Gastrointest Oncol       Date:  2018-12

10.  Surgical Treatment of Combined Hepatocellular-Cholangiocarcinoma is as Effective in Elderly Patients as it is in Younger Patients: A Propensity Score Matching Analysis.

Authors:  Chen-Yang Tao; Wei-Ren Liu; Lei Jin; Zheng Tang; Meng-Xin Tian; Xi-Fei Jiang; Han Wang; Pei-Yun Zhou; Yuan Fang; Zhen-Bin Ding; Yuan-Fei Peng; Zhi Dai; Shuang-Jian Qiu; Jian Zhou; Jia Fan; Ying-Hong Shi
Journal:  J Cancer       Date:  2018-02-28       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.